The phase 3 Keynote-181 study assessing Keytruda as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has achieved a primary endpoint of
Study results, published online in Cell Reports, showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges.
The financing was led by Hillhouse Capital Management and Quan Capital, and included Bay City Capital, Surveyor Capital (a Citadel company), Ping An Ventures, Taiho Ventures LLC, ArrowMark
The analysis, which is part of the 3b Expedition-8 study, assessed the safety and efficacy of Mavyret in treatment-naïve chronic hepatitis C virus (HCV) patients with compensated cirrhosis
The FDA and the Company have agreed to meet in-person on January 31, 2019 to discuss this matter. Remoxy is the proposed trade name for a new type
Aimmune Therapeutics is engaged in the development of advanced treatments for life-threatening food allergies. The latest investment brings Nestlé’s total investment in the drug developer for food allergies
OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment. Harpoon’s existing investors MPM Capital, Oncology
GS-9674 is an investigational, selective and non-steroidal agonist of the (FXR), which is a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR
VIS649 is a monoclonal antibody targeting the B-cell growth factor APRIL (A Proliferation Inducing Ligand) for the potential treatment of imumuglobulin A nephropathy (IgA nephropathy or IgAN), one
The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.